Miguel-Reyes JL, Gochicoa-Rangel L, Pérez-Padilla R, Torre-Bouscoulet L

Language: English
References: 44
Page: 5-14
PDF size: 256.47 Kb.

ABSTRACT

Interstitial lung diseases are a heterogeneous group of disorders that affect, to a greater or lesser degree, the alveolus, peripheral airway, and septal interstitium. Functional assessment in patients suspected of having an interstitial lung disease has implications for diagnosis and makes it possible to objectively analyze both response to treatment and prognosis. Recently the clinical value of lung-diffusing capacity and the six-minute walking test has been confirmed, and these are now important additions to the traditional assessment of lung function that is based on spirometry. Here we review the state-of-the-art methods for the assessment of patients with interstitial lung disease.

REFERENCES

1. Demedts M, Costabel U. ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Eur Respir J. 2002;19:794-6.

2. Selman M, Spagnolo P, Richeldi L. Interstitial lung disease in elderly subjects. Eur Resp Mon. 2009;43:150-62.

3. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733-48.

4. Danoff SK, Terry PB, Horton MR. A clinician’s guide to the diagnosis and treatment of interstitial lung diseases. South Med J. 2007;100:579-87.

5. ATS/ERS. International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2002;165:277-304.

6. American Thoracic Society/European Respiratory Society. Update of the International Multidisciplinary Classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733-48.

7. Keir G WA. Assessing pulmonary disease and response to therapy: Which test? Semin Respir Crit Care Med. 2010;31:409-18.

8. Vargas-Domínguez C, Gochicoa L, Velázquez M. Pruebas de función respiratoria, ¿cuál y a quién? Neumol Cir Torax. 2011; 70:99-115.

9. Keir G, Wells AU. Assessing pulmonary disease and response to therapy: which test? Semin Respir Crit Care Med. 2010;31:409-18.

10. Aaron SD, Dales RE, Cardinal P. How accurate is spirometry at predicting restrictive pulmonary impairment? Chest. 1999;115: 869-73.

11. du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011;184:1382-9.

12. Collard HR, King TE, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168:538-42.

13. du Bois R WD, Albera C, et al. Forced vital capacity In patients with idiopathic pulmonary fibrosis and minimal clinically important difference. Am J Respir Crit Care Med. 2011;184:1382-9.

14. Marciniuk DD, Sridhar G, Clemens RE, Zintel TA, Gallagher CG. Lung volumes and expiratory flow limitation during exercise in interstitial lung disease. J Appl Physiol. 1994;77:963-73.

15. Selman-Lama M, Perez-Padilla R. Airflow obstruction and airway lesions in hypersensitivity pneumonitis. Clin Chest Med. 1993; 14:699-714.

16. Perez-Padilla R, Torre-Bouscoulet L, Muino A, et al. Prevalence of oxygen desaturation and use of oxygen at home in adults at sea level and at moderate altitude. Eur Respir J. 2006;27:594-9.

17. Harris-Eze AO, Sridhar G, Clemens RE, Zintel TA, Gallagher CG, Marciniuk DD. Role of hypoxemia and pulmonary mechanics in exercise limitation in interstitial lung disease. Am J Respir Crit Care Med. 1996;154:994-1001.

18. Rudd RM, Haslam PL, Turner-Warwick M. Cryptogenic fibrosing alveolitis. Relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am Rev Respir Dis. 1981;124:1-8.

19. Agusti AG, Roca J, Gea J, Wagner PD, Xaubet A, Rodriguez- Roisin R. Mechanisms of gas-exchange impairment in idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1991;143:219-25.

20. Hansen JE. Pathophysiology of activity limitation in patients with interstitial lung disease. Chest. 1996;109:1566.

21. Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2012;185:1044-8.

22. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824.

23. Horstman M, Mertens F, Stam H. Transfer factor for carbon monoxide. Eur Resp Mon. 2005;31:127-45.

24. ATS/ERS TASK FORCE. Standarisation of lung function testing. Eur Respir J. 2005;26:720-35.

25. Krogh M. The diffusion of gases through the lungs of man. J Physiol. 1915;49:271-300.

26. Dujic Z, Tocilj J, Eterovic D. Increase of lung transfer factor in early sarcoidosis. Respir Med. 1995;89:9-14.

27. van der Lee I ZP, Grutters j, Snijder R, van den Bosch J. Diffusing capacity for nitric oxide and carbon monoxide in patients with diffuse parenchimal lung disease and pulmonary arterial hypertension. Chest. 2006;129:378-83.

28. Sandoval J, Lupi E, Gaspar J, Seoane M, Casanova JM. [Active and passive factors in the genesis of pulmonary arterial hypertension in various cardiopathies and pneumopathies]. Arch Inst Cardiol Mex. 1981;51:67-74.

29. Pitsiou G, Papakosta D, Bouros D. Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Respiration. 2011;82: 294-304.

30. Shlobin OA, Nathan SD. Pulmonary hypertension secondary to interstitial lung disease. Expert Rev Resp. 2011;5:179-89.

31. du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2011; 183:1231-7.

32. Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute- walk test. Am J Respir Crit Care Med. 2006;174:803-9.

33. Lederer DJ, Arcasoy SM, Wilt JS, D’Ovidio F, Sonett JR, Kawut SM. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006; 174:659-64.

34. Lettieria CJ NS, Browninga R, Barnettb S, Ahmadb S, Shorrc A. The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. Respir Med. 2006;100:1734-41.

35. Swigris JJ, Olson AL, Shlobin OA, Ahmad S, Brown KK, Nathan SD. Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respirology. 2011;16:439-45.

36. Deboeck G, Scoditti C, Huez S, et al. Exercise testing to predict outcome in idiopathic versus associated pulmonary arterial hypertension. Eur Respir J. 2012;40:1410-19.

37. Fell CD, Liu LX, Motika C, et al. The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179:402-7.

38. Zisman DA, Ross DJ, Belperio JA, et al. Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med. 2007; 101:2153-9.

39. Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest. 2007;131:657-63.

40. Cottin V, Cordier JF. The syndrome of combined pulmonary fibrosis and emphysema. Chest. 2009;136:1-2.

41. Cottin V, Le Pavec J, Prevot G, et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J. 2010;35:105-11.

42. Olson AL SJ, Lezotte DC, et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med. 2007;176:277-84.

43. Panos RJ MR, Niccoli SA, et al. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med. 1990;88:396-404.

44. Harari S, Caminati A. Update on diffuse parenchymal lung disease. Eur Respir Rev. 2010;19:97-108.